Researchers: Vertex's Kalydeco a big step, but combination approach may be leap
This article was originally published in Scrip
Executive Summary
While Vertex Pharmaceuticals' experimental cystic fibrosis (CF) drug Kalydeco (ivacaftor/VX-770), whose application currently is before the US FDA, has the potential to be the first marketed drug aimed at attacking the basic defect involved in the disease – marking one of the greatest strides forward in CF – researchers believe the next big step, and the one that will affect a broader population, is with its use as part of a combination therapy (scripintelligence, 20 October 2011).